FORTRINNSRETTSEMISJON

Med grunnlag i styrefullmakter tildelt av den ordinære generalforsamlingen i NattoPharma ASA ("NattoPharma" eller "Selskapet") den 25. juni 2015 og 20. mai 2016, har styret i Selskapet i styremøte 24. juni 2016, vedtatt å utstede 305 000 nye aksjer, hver med en nominell verdi på NOK 3 pr aksje.

Fortrinnsrettsemisjonen vil bli gjennomført ved utstedelse av aksjer til ledende ansatte i forbindelse med selskapets incentiv program i henhold til følgende fordeling;

Navn   Stilling   Tildelte Aksjer   Aksjer før tildeling   Aksjer etter tildeling  
Daniel H. Rosenbaum   CEO                   100.000   0                   100.000  
Kjetil Ramsøy   CFO                   100.000   0                   100.000  
Eric Anderson   VP Sales & Marketing                     50.000   0                     50.000  
Rudi de Man   VP Sales Europe & Asia                     30.000   0                     30.000  
William Sommer VP Global Development and Regulatory                     25.000   0                     25.000  

Pris på aksjene ved nytegning er NOK 3 pr aksje. Fortrinnsrettsemisjonen er forventet å være gjennomført innen 31. juli 2016.

Som en følge av emisjonen vil Selskapets aksjekapital øke med NOK 915 000. Selskapets nye aksjekapital etter gjennomføring av Fortrinnsrettsemisjonen vil være NOK 52 334 799 fordelt på 17 444 933 aksjer, hver pålydende NOK 3.

* * *

For nærmere informasjon, vennligst kontakt:

Kjetil Ramsøy, Chief Financial Officer

E-post: kjetil.ramsoy@nattopharma.com

Informasjonen i denne meldingen er offentliggjort i samsvar med verdipapirhandelloven § 5-12.

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.

Subscribe

Documents & Links